ARVO
Posted onDid you meet us in the Association for Research in Vision and Ophthalmology (ARVO), 7-11 May 2017 in Baltimore? Would you like to know more about our ophthalmology program? Contact us in contact@neurizon-pharma.com
Microbiology commitment
Posted on
Synovo’s presence in the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Better Use of Antibiotics Prize
Posted on
Synovo GmbH and Qualizyme diagnostics collaboration: Finalists for the Better Use of Antibiotics Prize An innovative detection system for airway infections developed by the collaboration between Synovo GmbH and Qualizyme diagnostics within the top 3 finalists for the Better Use of Antibiotics Prize by the European Commission.
Vision
Posted on
The European-funded project VISION has come to an end, but enormous achievements have been made and this is not the end but the beginning of the next phase. Let us introduce you to Neurizon Pharma.
Folsmart kick-off meeting
Posted on
The FOLSMART Kick-off meeting took place in Brussels last week. FOLSMART, Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis, granted by the European Commission within the Horizon 2020.
DIN EN ISO 9001
Posted on
We have been certified for the worldwide accepted quality standard DIN EN ISO 9001.
Synovo and ophthalmology
Posted on
We expand business to ophthalmology Tübingen, Germany, February 2014. Synovo, a company focused on drug discovery and preclinical development, today announced the strategic decision to extend its service portfolio on ophthalmic indications. Read more Synovo wird Anbieter für Dienstleistungen und Lösungen für Forschung und Entwicklung in der Augenheilkunde Tübingen, Februar 2014. Synovo, Spezialist für Identifikation […]
10 years of Synovo
Posted on
Synovo 10 years anniversary on Nov 2014 was a total success. Thank you!
Orphan designation for pancreatic cancer
Posted on
Orphan designation for SYD003 for the treatment of pancreatic cancer. Granted by the European Medicines Agency (EMA) on 22 August 2014 and by the US Food and Drug Administration (FDA) on 20 October 2014.
Orphan designation for treatment of CF
Posted on
Our compound SYD0073 has been granted orphan designation (EU/3/14/1239) by the European Medicines Agency (EMA) for the treatment of cystic fibrosis.